A phase i trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood

Neuro-Oncology

Volumn 10, Issue 4, 2008, Pages 569-576

  Jakacki, Regina I ^a   Yates, Allan ^b   Blaney, Susan M ^c   Zhou, Tianni ^d,e   Timmerman, Robert ^f   Ingle, Ashish M ^e   Flom, Lynda ^a   Prados, Michael D ^g   Adamson, Peter C ^h   Pollack, Ian F ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

CCNU (lomustine); Malignant glioma; Pediatrics; Temozolomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ETOPOSIDE; HEMOGLOBIN; LOMUSTINE; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACTEREMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; FEVER; GLIOBLASTOMA; GLIOMA; HERPES ZOSTER; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; BRAIN TUMOR; MULTICENTER STUDY;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; GLIOMA; HUMANS; LOMUSTINE; MAXIMUM TOLERATED DOSE;

EID: 54049115187     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-019     Document Type: Article

References (31)

1. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/ or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978;49:333-343.
2. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytomas in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7:165-177.
3. Green SB, Byar DP, Walker MD, et al. Comparison of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983;67:121-132.
4. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
5. Pollack IF, Boyett JM, Yates AJ, et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro-Oncology. 2003;5:197-207.
6. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007;110:1542-1550.
7. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup study. J Clin Oncol. 2002;20:4684-4691.
8. Plowman J, Waud WR, Koutsoukos AD, et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1994;54:3793-3799.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine and prednisone with the eight drugs in 1 day regimen. J Clin Oncol. 1995;13:112-123.
11. MacDonald TJ, Arenson EB, Ater J, et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer. 2005;104:2862-2871.
12. Wolff JE, Gnekow AK, Kortmann RD, et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer. 2002;94:264-271.
13. Chintagumpala MM, Friedman HS, Stewart CF, et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the Children's Oncology Group. J Neurooncol. 2006;77:193-198.
14. Prados MD, Yung A, Fine HA, et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro-Oncology. 2004;6:33-37.
15. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]- 1,2,3,5-tetrazin-4(3H)-one (CCRG 81045;M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47:5846-5852.
16. Newlands ES, Blackledge GRP, Slack JA, et al. Phase I trial of temozolomide. Br J Cancer. 1992;65:287-291.
17. Hammond LA, Eckardt JR, Kuhn JG, et al. A randomized phase I and pharmacological trial of sequences of 1-3-bis(2-chloroethyl)-1- nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res. 2004;10:1645-1656.
18. Wheeler KT, Deen DF, Wilson CB, et al. BCNU-modification of the in vitro radiation response in 9L brain tumor cells of rats. Int J Radiat Oncol Biol Phys. 1977;2:79-88.
19. Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: incidence, outcomes and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:499-508.
20. de Wit MCY, de Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63:535-537.
21. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography. Am J Neuroradiol. 1998;19:407-413.
22. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81-83.
23. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with gliobastoma multiforme. Neuro-Oncology. 2007;9:29-38.
24. Benesch M, Wagner S, Berthold F, et al. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group. J Neurooncol. 2005;72:179-183.
25. Dropcho EJ, Wisoff JH, Walker RW, et al. Supratentorial malignant gliomas in childhood: a review of fifty cases. Ann Neurol. 1987;22: 355-364.
26. Heideman RL, Kuttesch J, Gajjar A, et al. Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer. 1997;80: 497-504.
27. Grabb PA, Albright AL, Pang D. Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children. Neurosurgery. 1992;30:64-71.
28. Gururangan S, McLaughlin CA, Brashears J, et al. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol. 2006;77:207-212.
29. Vaidya SJ, Hargrave D, Saran F, et al. Pattern of recurrence in paediatric malignant glioma: an institutional experience. J Neurooncol. 2007;83:279-284.
30. Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group Trial No. CCG-945. J Neurosurg. 1998;89:52-59.
31. 2-methylguanine- DNA- methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol. 2006;24:3431-3437.